Do analysts recommend KTTA or VIVS?

Pasithea Therapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 559.63%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Pasithea Therapeutics is more favorable than VivoSim Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pasithea Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor KTTA or VIVS?

In the previous week, VivoSim Labs had 11 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 12 mentions for VivoSim Labs and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.00 beat VivoSim Labs' score of 0.43 indicating that Pasithea Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive VivoSim Labs 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer FNCH or VIVS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend VIVS or MYNZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is VIVS or MYNZ more profitable?

Mainz Biomed has a net margin of 0.00% compared to VivoSim Labs' net margin of -10,567.17%. Mainz Biomed's return on equity of 0.00% beat VivoSim Labs' return on equity. Company Net Margins Return on Equity Return on Assets VivoSim Labs -10,567.17% -277.62% -153.77% Mainz Biomed N/A N/A N/A

Does the media refer more to VIVS or MYNZ?

In the previous week, VivoSim Labs had 11 more articles in the media than Mainz Biomed. MarketBeat recorded 12 mentions for VivoSim Labs and 1 mentions for Mainz Biomed. VivoSim Labs' average media sentiment score of 0.43 beat Mainz Biomed's score of 0.00 indicating that VivoSim Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VivoSim Labs 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mainz Biomed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend VIVS or KPRX?

Kiora Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 295.26%. Given Kiora Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than VivoSim Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kiora Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

VivoSim Labs (VIVS) Competitors

$0.45 -0.05 (-10.87%)

Closing price 04:00 PM Eastern

Extended Trading

$0.48 +0.03 (+7.56%)

As of 05:12 PM Eastern

Compare

VIVS vs. KTTA, FNCH, MYNZ, KPRX, and CMMB

Should you buy VivoSim Labs stock or one of its competitors? MarketBeat compares VivoSim Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with VivoSim Labs include Pasithea Therapeutics (KTTA), Finch Therapeutics Group (FNCH), Mainz Biomed (MYNZ), Kiora Pharmaceuticals (KPRX), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry.

How does VivoSim Labs compare to Pasithea Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

VivoSim Labs has higher revenue and earnings than Pasithea Therapeutics. Pasithea Therapeutics is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
VivoSim Labs	$131K	12.00	-$13.84M	-$5.36	N/A

23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are held by institutional investors. 2.0% of Pasithea Therapeutics shares are held by insiders. Comparatively, 2.5% of VivoSim Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Pasithea Therapeutics has a net margin of 0.00% compared to VivoSim Labs' net margin of -10,567.17%. Pasithea Therapeutics' return on equity of -57.44% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
VivoSim Labs	-10,567.17%	-277.62%	-153.77%

In the previous week, VivoSim Labs had 11 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 12 mentions for VivoSim Labs and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.00 beat VivoSim Labs' score of 0.43 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
VivoSim Labs	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pasithea Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

Pasithea Therapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 559.63%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Pasithea Therapeutics is more favorable than VivoSim Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Pasithea Therapeutics beats VivoSim Labs on 10 of the 16 factors compared between the two stocks.

How does VivoSim Labs compare to Finch Therapeutics Group?

Finch Therapeutics Group (NASDAQ:FNCH) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

In the previous week, VivoSim Labs had 12 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 12 mentions for VivoSim Labs and 0 mentions for Finch Therapeutics Group. VivoSim Labs' average media sentiment score of 0.43 beat Finch Therapeutics Group's score of 0.00 indicating that VivoSim Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
VivoSim Labs	Neutral

Finch Therapeutics Group has a net margin of 0.00% compared to VivoSim Labs' net margin of -10,567.17%. Finch Therapeutics Group's return on equity of -69.14% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
VivoSim Labs	-10,567.17%	-277.62%	-153.77%

21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 2.5% of VivoSim Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

VivoSim Labs has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
VivoSim Labs	$131K	12.00	-$13.84M	-$5.36	N/A

Finch Therapeutics Group has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

VivoSim Labs beats Finch Therapeutics Group on 8 of the 13 factors compared between the two stocks.

How does VivoSim Labs compare to Mainz Biomed?

VivoSim Labs (NASDAQ:VIVS) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

VivoSim Labs has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

8.2% of VivoSim Labs shares are owned by institutional investors. 2.5% of VivoSim Labs shares are owned by company insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, VivoSim Labs had 11 more articles in the media than Mainz Biomed. MarketBeat recorded 12 mentions for VivoSim Labs and 1 mentions for Mainz Biomed. VivoSim Labs' average media sentiment score of 0.43 beat Mainz Biomed's score of 0.00 indicating that VivoSim Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VivoSim Labs	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mainz Biomed	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

VivoSim Labs has higher earnings, but lower revenue than Mainz Biomed. VivoSim Labs is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VivoSim Labs	$131K	12.00	-$13.84M	-$5.36	N/A
Mainz Biomed	$659.94K	15.93	-$21.65M	-$65.60	N/A

Mainz Biomed has a net margin of 0.00% compared to VivoSim Labs' net margin of -10,567.17%. Mainz Biomed's return on equity of 0.00% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VivoSim Labs	-10,567.17%	-277.62%	-153.77%
Mainz Biomed	N/A	N/A	N/A

Summary

Mainz Biomed beats VivoSim Labs on 8 of the 14 factors compared between the two stocks.

How does VivoSim Labs compare to Kiora Pharmaceuticals?

VivoSim Labs (NASDAQ:VIVS) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Kiora Pharmaceuticals has a net margin of 0.00% compared to VivoSim Labs' net margin of -10,567.17%. Kiora Pharmaceuticals' return on equity of -59.30% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VivoSim Labs	-10,567.17%	-277.62%	-153.77%
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%

VivoSim Labs has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.4, meaning that its stock price is 140% less volatile than the broader market.

8.2% of VivoSim Labs shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 2.5% of VivoSim Labs shares are owned by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, VivoSim Labs had 12 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 12 mentions for VivoSim Labs and 0 mentions for Kiora Pharmaceuticals. VivoSim Labs' average media sentiment score of 0.43 beat Kiora Pharmaceuticals' score of 0.00 indicating that VivoSim Labs is being referred to more favorably in the media.

Company	Overall Sentiment
VivoSim Labs	Neutral
Kiora Pharmaceuticals	Neutral

Kiora Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 295.26%. Given Kiora Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than VivoSim Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Kiora Pharmaceuticals has higher revenue and earnings than VivoSim Labs. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VivoSim Labs	$131K	12.00	-$13.84M	-$5.36	N/A
Kiora Pharmaceuticals	$16.02M	0.70	-$10.84M	-$2.71	N/A

Summary

Kiora Pharmaceuticals beats VivoSim Labs on 10 of the 16 factors compared between the two stocks.

How does VivoSim Labs compare to Chemomab Therapeutics?

Chemomab Therapeutics (NASDAQ:CMMB) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Chemomab Therapeutics has a net margin of 0.00% compared to VivoSim Labs' net margin of -10,567.17%. Chemomab Therapeutics' return on equity of -89.03% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-89.03%	-79.68%
VivoSim Labs	-10,567.17%	-277.62%	-153.77%

46.1% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by company insiders. Comparatively, 2.5% of VivoSim Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Chemomab Therapeutics has higher earnings, but lower revenue than VivoSim Labs. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A
VivoSim Labs	$131K	12.00	-$13.84M	-$5.36	N/A

In the previous week, VivoSim Labs had 12 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 12 mentions for VivoSim Labs and 0 mentions for Chemomab Therapeutics. VivoSim Labs' average media sentiment score of 0.43 beat Chemomab Therapeutics' score of 0.00 indicating that VivoSim Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
Chemomab Therapeutics	Neutral
VivoSim Labs	Neutral

Chemomab Therapeutics currently has a consensus price target of $25.00, suggesting a potential upside of 1,600.68%. Given Chemomab Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Chemomab Therapeutics is more favorable than VivoSim Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Chemomab Therapeutics has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

Summary

Chemomab Therapeutics beats VivoSim Labs on 10 of the 15 factors compared between the two stocks.

Get VivoSim Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VIVS vs. The Competition

Export

Metric	VivoSim Labs	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.57M	$3.65B	$6.81B	$12.41B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-0.08	20.79	27.00	24.19
Price / Sales	12.00	321.78	518.84	94.59
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	-1.07	8.17	10.67	6.26
Net Income	-$13.84M	$23.81M	$3.60B	$331.76M
7 Day Performance	-46.09%	-1.16%	-0.37%	-1.10%
1 Month Performance	-59.09%	2.60%	1.85%	-1.27%
1 Year Performance	-77.27%	45.44%	25.51%	18.85%

VivoSim Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VIVS VivoSim Labs	0.428 of 5 stars	$0.45 -10.9%	N/A	-73.3%	$1.57M	$131K	N/A	20	Earnings Report Gap Up High Trading Volume
KTTA Pasithea Therapeutics	3.6831 of 5 stars	$0.46 -4.4%	$3.00 +556.2%	-34.3%	$11.92M	N/A	N/A	3	News Coverage Positive News
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190
MYNZ Mainz Biomed	0.2262 of 5 stars	$1.23 -2.4%	N/A	-34.9%	$11.14M	$659.94K	N/A	30	News Coverage Gap Down
KPRX Kiora Pharmaceuticals	2.3338 of 5 stars	$2.55 +2.8%	$10.00 +292.2%	-18.2%	$10.99M	$16.02M	N/A	10	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VIVS) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

VivoSim Labs (VIVS) Competitors

VIVS vs. KTTA, FNCH, MYNZ, KPRX, and CMMB

How does VivoSim Labs compare to Pasithea Therapeutics?

Summary

How does VivoSim Labs compare to Finch Therapeutics Group?

Summary

How does VivoSim Labs compare to Mainz Biomed?

Summary

How does VivoSim Labs compare to Kiora Pharmaceuticals?

Summary

How does VivoSim Labs compare to Chemomab Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIVS vs. The Competition

VivoSim Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

VivoSim Labs (VIVS) Competitors

VIVS vs. KTTA, FNCH, MYNZ, KPRX, and CMMB

How does VivoSim Labs compare to Pasithea Therapeutics?

Which has stronger valuation and earnings, KTTA or VIVS?

Do institutionals & insiders have more ownership in KTTA or VIVS?

Is KTTA or VIVS more profitable?

Does the media favor KTTA or VIVS?

Which has more risk and volatility, KTTA or VIVS?

Do analysts recommend KTTA or VIVS?

Summary

How does VivoSim Labs compare to Finch Therapeutics Group?

Does the media prefer FNCH or VIVS?

Is FNCH or VIVS more profitable?

Do insiders and institutionals have more ownership in FNCH or VIVS?

Which has stronger valuation & earnings, FNCH or VIVS?

Which has more volatility & risk, FNCH or VIVS?

Do analysts prefer FNCH or VIVS?

Summary

How does VivoSim Labs compare to Mainz Biomed?

Which has more volatility & risk, VIVS or MYNZ?

Do analysts recommend VIVS or MYNZ?

Do insiders and institutionals believe in VIVS or MYNZ?

Does the media refer more to VIVS or MYNZ?

Which has higher earnings and valuation, VIVS or MYNZ?

Is VIVS or MYNZ more profitable?

Summary

How does VivoSim Labs compare to Kiora Pharmaceuticals?

Is VIVS or KPRX more profitable?

Which has more volatility and risk, VIVS or KPRX?

Do institutionals & insiders believe in VIVS or KPRX?

Does the media favor VIVS or KPRX?

Do analysts recommend VIVS or KPRX?

Which has better valuation and earnings, VIVS or KPRX?

Summary

How does VivoSim Labs compare to Chemomab Therapeutics?

Is CMMB or VIVS more profitable?

Do insiders & institutionals have more ownership in CMMB or VIVS?

Which has stronger earnings and valuation, CMMB or VIVS?

Does the media prefer CMMB or VIVS?

Do analysts prefer CMMB or VIVS?

Which has more risk & volatility, CMMB or VIVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIVS vs. The Competition

VivoSim Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools